Cost Analysis of Enzyme Replacement Therapy Domicile Infusion in the Fabry Disease

Author(s)

Mignani R1, Tedone F2, Lopatriello S3, Cafiero D2
1Rimini AUSL, Rimini, Italy, 2Helaglobe S.r.L, Firenze, Italy, 3Helaglobe S.r.L, Roma, RM, Italy

OBJECTIVES:

Anderson-Fabry and Gaucher are genetic disorders caused by lysosomal enzyme deficiencies [1]. Enzyme replacement therapy, administered by periodic intravenous infusions in the hospital setting, controls underlying enzyme deficiency. Hospital-based infusion implies patients travels and waits at referral centres, which might interfere with their and caregivers daily life activities. Domicile infusion can improve therapy adherence and quality of life [2]. However, additional resources consumption could be required. This study aimed at comparing domicile and hospital-based infusion costs and identifying savings impact factors.

METHODS:

An Excel model was populated by semi-structured questionnaire: times and procedure protocol were retrieved from the referral centre of Rimini, Emilia Romagna Region. Unit costs were from literature. Sensitivity analysis was performed by modifying hospital fixed cost, domicile nurse working schedule and salary, specialist visit cost, number of nurse per patient and infusion duration.

RESULTS:

Base case results showed 272.13€ saving per patient in the domicile setting. Drivers of cost are hourly nurse salary (30€/h in the base case) and total journey kilometres (30km in the base case). Saving vanished if hourly operator’s salary increased by 18.9% (35.67€/h) or if kilometres of journey increased by 63% (48.9km). Hospital fixed cost (150€/day) (91% reduction), infusion duration (exceeding of 3 hours) and number of hospital nurses per patient (ratio 2:3 which might be up to ratio 2:5) did not nullify cost savings. Finally, specialist cost (50.77€/h in the basecase) had no impact on saving.

CONCLUSIONS:

Enzyme replacement therapy domicile infusion therapy saves NHS costs if implemented with specific procedure features. The model is reproducible in other centres due to the robustness of the sensitivity analysis implemented and it is a valuable decision-maker tool.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)

Code

EE235

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×